Treatment News : PRO 140 Shows Promise in Single-Dose Study - by Tim Horn

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » August 2007

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

August 1, 2007

PRO 140 Shows Promise in Single-Dose Study

by Tim Horn

Researchers at the fourth IAS Conference on HIV Pathogenesis, Treatment and Prevention, in Sydney, reported encouraging results from an early study of PRO 140, an experimental HIV entry inhibitor. Of particular interest was the fact that viral loads remained 90 percent below pretreatment levels two to three weeks after a single dose of the drug.

PRO 140 is a laboratory-made antibody that binds to a protein on the CCR5 membrane of CD4 cells. Once it does this, HIV cannot successfully bind with the surface of CD4s; thus the virus is prevented from infecting healthy cells.

While Pfizer’s maraviroc, which is being considered for approval by the U.S. Food and Drug Administration, works differently than PRO 140, both drugs target CCR5 and are being tested as HIV entry inhibitors.

Progenics’ clinical trial, conducted at 10 sites in the United States, examined three single intravenous doses of PRO 140: 0.5 milligram per kilogram (mg/kg) of body weight, 2.0 mg/kg and 5.0 mg/kg. A total of 39 HIV-positive patients, none of whom had used antiretrovirals in the past, were enrolled in the study.

All patients were screened prior to the study for the presence of virus that utilizes only CCR5 as its entry coreceptor (as opposed to the CXCR4 coreceptor). Of the 13 patients in each dosing group, 10 patients received PRO 140 and three received placebo.

No other HIV medications were taken in the study.

Viral load reductions were the chief focus of the study. Patients who received 5.0 mg/kg of PRO 140 achieved an average maximum viral load drop of 1.83 log, with some patients achieving viral load reductions of 2.5 log.

Ten days after receiving single-dose PRO 140, viral loads dropped by an average of 1.7 log in the 5.0 mg/kg group, compared to average reductions of 1.2 log in the 2.0 mg/kg group, 0.58 log in the 0.5 mg/kg group and 0.39 log in the placebo group. And after two to three weeks, patients who received 5.0 mg/kg PRO 140 still averaged viral loads 1.0 log below pretreatment levels.

CD4 counts increased, on average, by 129 cells in the 5.0 mg/kg PRO 140 group by day eight. The elevations in all groups persisted for approximately three weeks after the drug was administered.

Additionally, the study found PRO 140 to be generally well tolerated with no serious drug-related adverse events reported. Two of the 39 patients in the study experienced a switch in their HIV tropism, from CCR5-using virus to dual-tropic (CCR5 and CXCR4) virus.

Progenics also reported that it has developed a subcutaneous injection version of PRO 140. Based on favorable laboratory tests, the company plans to advance the subcutaneous formulation into clinical trials later this year, with the goal of developing a long-acting self-administered therapy for HIV infection.

Source:

Saag MS, Jacobson JM, Thompson M, et al. Antiviral effects and tolerability of the CCR5 monoclonal antibody PRO 140: a proof of concept study in HIV-infected individuals [Abstract WESS201]. Fourth IAS Conference on HIV Pathogenesis, Treatment and Prevention, Sydney, 2007.


[Go to top]


Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    guycmh328
    Columbus
    Ohio


    Sin_Grinder
    Reno
    Nevada


    ernienyc
    Bronx
    New York


    donnyp
    liberty
    Kentucky
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Are you a regular coffee drinker?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.